HeraMED Ltd. (1I4) Stock Price & Analysis
1I4 Stock Chart & Stats
- Day’s Range
- EUR 0.02 - EUR 0.03
- 52-Week Range
- EUR 0.02 - EUR 0.06
- Previous Close
- EUR 0.02
- Volume
- 0
- Average Volume (3M)
- 18.83K
- Market Cap
- EUR 26.89M
- Enterprise Value
- EUR 39.94M
- Total Cash (Recent Filing)
- EUR 2.03M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.99
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin Improvement
The improvement to roughly 60% gross margin shows that the company’s offerings can generate positive contribution after direct costs. If maintained, this creates a stronger foundation for scaling revenue, funding product development, and eventually converting improved unit economics into operating profitability.
Deleveraged Balance Sheet
Eliminating debt reduces interest obligations and lowers balance-sheet risk compared with 2021, when equity was negative and debt was elevated. Positive equity also provides a more stable financial base, although the small remaining cushion limits the protection this improvement provides.
Improving Cash Burn
The reduction in cash burn indicates some improvement in cash discipline and may extend the period before additional funding is required. While cash generation remains negative, a sustained improvement would strengthen financial flexibility and provide more time to convert the business model into positive operating cash flow.
Bears Say
Revenue Contraction
Recent revenue contraction weakens the company’s ability to spread fixed operating costs across a growing base and makes a path to profitability less certain. Continued volatility or decline could constrain investment capacity, reduce operating leverage, and limit the commercial impact of its digital health platform.
Persistent Operating Losses
Ongoing operating and net losses show that improved gross margin has not yet translated into a sustainable earnings model. Persistent losses can consume equity, restrict reinvestment, and make the company more dependent on future financing or stronger revenue growth to achieve commercial viability.
Negative Cash Generation
Consistently negative operating and free cash flow means the business is still consuming cash to operate rather than self-funding growth. This raises longer-term liquidity and funding risk, particularly because continued losses and a reduced equity base leave less room to absorb further cash requirements.
HeraMED Ltd. News
1I4 FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
What is HeraMED Ltd.’s market cap?
When is HeraMED Ltd.’s upcoming earnings report date?
How were HeraMED Ltd.’s earnings last quarter?
Is HeraMED Ltd. overvalued?
Does HeraMED Ltd. pay dividends?
What is HeraMED Ltd.’s EPS estimate?
How many shares outstanding does HeraMED Ltd. have?
What happened to HeraMED Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HeraMED Ltd.?
What is the TipRanks Smart Score and how is it calculated?
HeraMED Ltd. Stock Smart Score
Company Description
HeraMED Ltd.
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Anoushka Gungadin
- Employees
- 6
- Website
- www.hera-med.com
- Address
- 117 Camberwell Road, Hawthorn East, VIC, 3123, AU
HeraMED Ltd. (1I4) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 13 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 1 | 1 | 10 |